Inhibition of Experimental Asthma in Man by a New Drug (AH 7725) Active when Given by Mouth

Assem, E. S. K.; Evans, J. A.; McAllen, Monica
April 1974
British Medical Journal;4/13/1974, Vol. 2 Issue 5910, p93
Academic Journal
No abstract available.


Related Articles

  • Drug therapy in the management of asthma. Vanarsdel Jr., Paul P.; Paul, Glennon H.; VanArsdel, P P Jr; Paul, G H // Annals of Internal Medicine;Jul77, Vol. 87 Issue 1, p68 

    In the past decade there has been substantial improvement in the quality of drug therapy for asthma. In part, this reflects the greater sophistication and confidence in the use of bronchodilator drugs, after their role in modifying the intracellular concentration of cyclic nucleotides was...

  • A risk-benefit assessment of antileukotrienes in asthma. Smith, L.J. // Drug Safety;Sep1998, Vol. 19 Issue 3, p205 

    The antileukotriene drugs are the first new therapeutic agents approved for the treatment of asthma in more than 20 years. The currently available compounds are orally active and either prevent the cysteinyl leukotrienes from binding to and activating the cysLT-1 receptor in the lung...

  • Overactive T cells may cause asthma. Brown, P. // New Scientist;2/15/92, Vol. 133 Issue 1808, p26 

    Reports on the latest work by British researchers who provided the strongest evidence that asthma results when cells in the immune system mistakenly become overactive. This opens the way for trials of a new generation of asthma drugs which block these cells. New findings confirm that activated...

  • Role of Dried Fruits of Carissa carandas as Anti-Inflammatory Agents and the Analysis of Phytochemical Constituents by GC-MS. Anupama, N.; Madhumitha, G.; Rajesh, K. S. // BioMed Research International;2014, Vol. 2014, p1 

    Inflammation plays an important role in various diseases with high prevalence within populations such as rheumatoid arthritis, ulcer, atherosclerosis, and asthma.Many drugs are available in themarket for inflammatory diseases.They exhibit several unwanted side effects to humans. Therefore,...

  • Aryl Hydrocarbon Receptor-Dependent Retention of Nuclear HuR Suppresses Cigarette Smoke-Induced Cyclooxygenase-2 Expression Independent of DNA-Binding. Zago, Michela; Sheridan, Jared A.; Nair, Parameswaran; Rico de Souza, Angela; Gallouzi, Imed-Eddine; Rousseau, Simon; Di Marco, Sergio; Hamid, Qutayba; Eidelman, David H.; Baglole, Carolyn J. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that responds to man-made environmental toxicants, has emerged as an endogenous regulator of cyclooxygenase-2 (Cox-2) by a mechanism that is poorly understood. In this study, we first used AhR-deficient...

  • Severe asthma and the omalizumab option. Miller, Christopher W. T.; Krishnaswamy, Narayanaswamy; Johnston, Chambless; Krishnaswamy, Guha // Clinical & Molecular Allergy;2008, Vol. 6, Special section p1 

    Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process in many patients is driven by an immunoglobulin E (IgE)-dependent process. Mast cell activation and...

  • The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor. O'Donnell, Edmond F.; Saili, Katerine S.; Koch, Daniel C.; Kopparapu, Prasad R.; Farrer, David; Bisson, William H.; Mathew, Lijoy K.; Sengupta, Sumitra; Kerkvliet, Nancy I.; Tanguay, Robert L.; Kolluri, Siva Kumar // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and differentiation, and recent studies have...

  • Asthma market gets an airing, therapy extends beyond drugs.  // Medical Marketing & Media;Jun98, Vol. 33 Issue 6, p20 

    Focuses on asthma therapy in the United States, in relation to an address given by experts at an American Medical Association press briefing in New York. Views that asthma is the most under-diagnosed chronic disease; Information on the therapeutic developments made in asthma drugs; Details on...

  • Drug highlight: Pilocarpine. Wilcock, Andrew; Twycross, Robert; Mortimer, Julie; Thresiamma, M. P. // Indian Journal of Palliative Care;Dec2006, Vol. 12 Issue 2, p65 

    The article provides information about drug Pilocarpine. It is a parasympathomimetic drug with mild β-adrenergic activity which stimulates secretion from exocrine glands . Its indications include xerostimia or dry mouth after radiation for head and neck cancer, dry mouth and eyes for...

  • Update on the use of montelukast in pediatric asthma. Capristo, Carlo; Rigotti, Erika; Boner, Attilio L. // Allergy & Asthma Proceedings;Jul/Aug2006, Vol. 27 Issue 4, p312 

    Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics